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INTRODUCTION 
Klebsiella pneumoniae is considered as one of a group of 
pathogens responsible for most of the multidrug-resistant 
(MDR) nosocomial infections, in intensive care units (ICUs) 
of various hospitals [1]. K. pneumoniae is a major cause of 
nosocomial infections, primarily among immuno-
compromised patients and those with long hospital stay. 
Emergence of MDR strains of K. pneumoniae has become a 
serious clinical concern for both patients’ treatment (increase 
of mortality) and hospital management system. The most 
frequent resistances include resistance to aminoglycosides, 
fluoroquinolones (FQs), tetracyclines, chloramphenicol, and 
trimethoprim/sulfamethoxazole [2]. Reported carrier rates of 
multi-resistant strains in hospitalized patients are 77%, 19% 
and 42% in samples from stool, pharynx and patients' hands, 
respectively [3]. The high rate of nosocomial K. pneumoniae 
colonization appears to be associated with the use of 
antibiotics rather than hospital sanitation problems. 
Ciprofloxacin is one of the treatment choices for 
infections caused by the Enterobacteriaceae family. This 
antibiotic acts by inhibiting bacterial DNA gyrase and 
topoisomerase IV, which are required for DNA replication 
[4]. Gyrase is more susceptible to inhibition by quinolones 
than topoisomerase IV, whereas, ciprofloxacin and 
levofloxacin are the two most frequently prescribed FQs. 
There are three mechanisms of resistance to quinolones: 1) 
mutations that alter the drug targets, 2) mutations that reduce 
drug accumulation, and 3) plasmids that protect cells from 
the lethal effects of quinolones [5]. 
Once a first-step mutation has reduced susceptibility of 
DNA gyrase in a Gram-negative organism, additional 
mutations in gyrA or mutations in gyrB or parC can further 
increase resistance to this class of antibiotics. Amino acid 
substitutions in a region of the gyrA or parC subunit, named 
“quinolone-resistance determining region” (QRDR), are 
involved in the resistance to quinolones. This region occurs 
on the DNA-binding surface of the enzyme [6]. 
 
 
Introduction: The objective of this study was to determine the amino acid substitutions in gyrA and parC proteins in certain 
clonal lineages of K. pneumoniae conferring high-level quinolone resistance. Methods: One hundred and eleven K. pneumoniae 
isolates were recovered from clinical specimens in a teaching hospital in Kerman, Iran. The antibiotic susceptibility and MIC of 
quinolones were determined according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Clonal lineages of the 
isolates were confirmed by enterobacterial repetitive intergenic consensus (ERIC)-PCR. Amino acid mutation profiles of gyrA 
and parC amplicons of 6 high quinolone-resistant isolates were also determined by DNA sequencing. Results: Twenty-two 
isolates were resistant to nalidixic acid (MIC, 256 µg/ml), ciprofloxacin (MIC, 32 µg/ml), levofloxacin (MIC, 32 µg/ml), and 
ofloxacin (MIC, 32 µg/ml). ERIC-PCR typing identified 4 clusters and 6 singleton, the largest belonged to cluster 3. Sequencing 
of gyrA gene showed 3 amino acid substitutions ( Ser83→Ile, Lys154→Arg, and Ser171→Ala) in the strains 18, 20, 33; two 
substitutions (Lysine154→Arg; Ser171→Ala) in the strains 27 and 65 and 6 substitutions in the strain 66, of which, 3 
(Ser83→Phe, Asp87→Ala, and Val190→Gly) were unique for this strain. Sequencing of parC gene revealed two substitutions 
(Ser129→Ala and Ala141→Val) in the strains 18, 27, 66, and 3 amino acid changes (Ser80→Ile, Ser129→Ala, and Ala141→Val) 
in the strains 20 and 33, respectively. Alignment and phylogenetic tree analysis of the gyrA from isolate 66 with homologous 
sequences obtained from the NCBI database, revealed 99.8% similarity to gyrA gene of K. pneumoniae ha10. Conclusion: The 
results suggest that acquisition of mutations in certain positions of gyrA and parC genes confers high-level resistance to 
quinolones. J Med Microbiol Infec Dis, 2014, 2 (3): 109-117. 
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Resistance to FQ is now common in many extended 
spectrum beta-lactamase (ESBL)-producing bacteria 
including K. pneumoniae [7]. FQ resistance has been 
associated with specific amino acid substitutions in the 
QRDRs in gyrA and B subunits of DNA gyrase and parC and 
parE subunits of topoisomerase IV [8]. Typically, in both 
laboratory and clinical isolates, alterations in the serine 
residue comprise more than 90% of the mutant pool, with 
changes in the acidic residues comprising the bulk of the 
other mutations [9]. Mutations at Ser83 and Asp87 codons 
of gyrA subunit and Ser80 and Glu84 codons of parC subunit 
have been frequently reported in FQ-resistant K. pneumoniae 
isolates worldwide [9]. 
The objective of the present study is to determine the 
amino acid substitutions of gyrA and parC proteins in certain 
clonal lineages of the K. pneumoniae conferring high-level 
quinolone resistance. 
 
MATERIAL AND METHODS 
Specimen collection and bacterial identification. A 
total of 111 consecutive, isolates of K. pneumoniae were 
recovered from clinical specimens, such as urine, blood, 
bronchial aspirate, sputum, and patients' wounds of in 
surgical wards, burn units, and intensive care units 
(including NICU) of a teaching hospital, Kerman, Iran from 
June 2013 to March 2014. Samples taken by an expert 
laboratory technician were initially inoculated on 
MacConkey and bood agar (Merck, Darmstadt, Germany) 
plates and incubated at 37°C for 24 h. All isolates were 
confirmed as K. pneumoniae by conventional diagnostic 
tests for Enterobacteriaceae as described previously [10]. 
Demographic characteristics, including, sex, age, hospital 
unit, and length of hospitalization, were recorded. The 
individual colonies were inoculated onto sterile True North 
TM Cryogenic Vials (TNC) containing 1 ml of sterile tryptic 
soy broth (TSB) (BioMérieux, Marcy-I’Etoile, France) 
mixed with glycerol (40%) and stored at -70°C for further 
study. 
Antimicrobial susceptibility testing. Antimicrobial 
susceptibility of all the hospital isolates of K. pneumoniae to 
four quinolones (nalidixic acid, ciprofloxacin, levofloxacin, 
and ofloxacin) was tested by the Kirby-Bauer agar disk 
diffusion breakpoint method [11]. The level of resistance 
was defined as: susceptible, intermediate, and resistant, 
based on the Clinical and Laboratory Standards Institute 
(CLSI) guidelines 2012 [12]. Oxoid antibiotic disks (Hi-
Media, Mumbai, India) were used in the following 
concentrations (µg/ml): ciprofloxacin, 5; levofloxacin, 5; 
nalidixic acid, 30; ofloxacin, 5. Well-isolated colonies were 
inoculated into 5 ml TSB medium and incubated at 37°C for 
24 h. The turbidity was then adjusted to 0.5 McFarland 
standard (CFU × 108). Two hundred microliters of the 
culture media were streaked on Muller-Hinton agar (Hi-
Media, Mumbai, India) and the antibiotic disks were placed 
on the surface of agar plates. The plates were incubated at 
37°C for 24 h and the inhibition zone around each disk was 
interpreted according to CLSI guidelines. 
Minimum inhibitory concentrations (MICs) in quinolone 
resistant isolates were determined by E-test strips (Hi-Media, 
Mumbai, India) on Mueller-Hinton agar (MHA) according 
to the instructions of the manufacturer and CLSI guidelines. 
Resistance to nalidixic acid, ciprofloxacin, levofloxacin, and 
ofloxacin was defined as an MIC ≥4 µg/mL, and the 
susceptibility was defined as an MIC ≤1 µg/ml. Escherichia 
coli ATCC 25922 was used as quality control strain. 
Molecular typing by ERIC-PCR. All quinolones 
resistant K. pneumoniae were typed by ERIC-PCR [13] to 
asses clonal relationships among the hospital isolates. 
Briefly, genomic DNA was extracted using a bacterial DNA 
extraction kit (Thermo Scientific, Vilnius, Lithuania) from a 
single colony grown on Luria- Bertani (LB) agar plates 
(BioMérieux, Marcy-l'Etoile, France) according to the 
manufacturer's instructions. The primers (Gene-Ray, 
Shanghai, China) used for ERIC-PCR typing were as follows; 
ERIC-1R (5'-AAGCTCCTGGGGATTCA-3') and ERIC-F 
(5'-AAGTAAGTGACTGGGGTGAGCG-3'). Each PCR 
amplification was performed on 50 µl of total volume 
containing 20 pM of target DNA, 0.2 mM of dNTPs, 50 pM 
of each primer, 5 µl of 10x PCR buffer solution (500 mM 
KCl, 100 mM Tris-HCl, pH 9.0), 2.5 mM MgCl2, and 2 units 
of Taq DNA Polymerase (Ampliqon, Denmark). PCR 
conditions were as follows: denaturation at 95°C for 5 min, 
40 cycles of denaturation at 92°C for 30 s, annealing at 59°C 
for 45 s, and extension at 72°C for 30 s. After reactions were 
completed, a final extension was performed at 72°C for 10 
min [14]. The PCR products were separated by 
electrophoresis on 1.3% agarose gels (Merck, Darmstadt, 
Germany) and visualized using a gel documentation system 
(UVTEC, Cambridge). PCR profiles obtained by ERIC 
primers were used for dendrogram analysis and fingerprints 
by PyElph 1.4 software based on UPGMA (unweighted pair 
group method with arithmetic averages). The similarities 
between the fingerprints were calculated using the Pearson 
correlation test. 
PCR amplification and sequencing of gyrA and parC 
genes. For PCR reactions, 22 quinolone resistant isolates of 
K. pneumoniae were grown on LB agar for 24 h at 37°C. 
Individual colonies were dissolved with 200 µl double 
distilled H20 and chromosomal DNA was extracted using a 
DNA extraction kit (Qiagen; Valencia, CA, USA). 
Oligonucleotide primers (Gene-Ray, Shanghai, China) used 
for amplification of the putative gyrA and parC genes, 
including QRDR were: gyrA-F (5´-
CGCGTACTATACGCCATGAACGTA-3´); gyrA-R (5´-
ACCGTTGATCACTTCGGTCAGG-3´); parC-F (5´-
GCGTTGCCGTTTATTGGTGAT-3´); and parC-R (5´-
GCAGGTTATGCGGTGGAAT-3´). PCR conditions for 
gyrA and parC amplifications consisted of an initial 
denaturation at 95°C for 30 s, followed by 30 cycles of 
denaturation at 95°C for 35 s, annealing at 62°C for 35 s for 
gyrA and at 59°C for 30 s for parC, extension at 72°C for 45 
s, and a final extension at 72°C for 30 s. The PCR products 
were sent for sequencing (Bioneer, Seoul-Korea) in both 
directions with the same set of primers used for the PCR by 
Sanger dideoxy chain termination method using an Applied 
Biosystems 3730/3730Xl DNA Analyser (API, California, 
USA). Similarity searches for the nucleotide sequences were 
performed by BLAST algorithm software 
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(http://www.ncbi.nlm.nih.gov/blast). Phylogenetic tree and 
evolutionary distance analysis of the gyrA gene of highly 
quinolone resistant isolate 66 were done by Maximum 
Likelihood method based on the Jones-Taylor-Thornton 
(JTT) matrix-based model and neighbour joining algorithms 
using MEGA6 software. Amino acid sequences of both gyrA 
and parC proteins were determined using UniProt database 
(http://www.uniprot.org) and compared for mutation 
analysis with reference sequences of Enterobacteriaceae 
gyrA and parC 281242.1 and NC_000913.3, respectively.  
Statistical analysis. All numerical data were analysed 
using SPSS software for Windows (version 19; SPSS Inc., 
Chicago, IL, USA). Pearson's chi‐square tests were used to 
evaluate the correlation between mutation and quinolone 
resistance. Statistical significance was defined as p‐value 
less than 0.05. 
 
RESULTS  
Quinolone susceptibility. Out of a total number of 111 
confirmed cases of K. pneumoniae infections in our hospital, 
66% had signs of urinary tract infection (UTI), with the 
length of hospital stay of 15 to 20 days, 14% admitted with 
lower respiratory infections, such as chronic obstructive 
pulmonary disease (COPD) and ventilator associated 
pneumonia (VAP) with the highest length of stay in the ICU 
(20-25 days), 11% had blood infection, and 9% had wound 
infection and abscess with 13-15 days length of stay in 
hospital, respectively (Table 1). Among the infected patients, 
53.2% were adult females, 32.4% were adult males, and 14.4% 
were infants. The majority (73%) of the patients aged from 
46 to 62 years.  
Antimicrobial susceptibility of all the isolates to four 
quinolone antibiotics are illustrated in Figure 1. Among the 
collected isolates, 22 (19%) were fully resistant to nalidixic 
acid and exhibited MIC ≥256 µg/ml, 77 (70%) were 
intermediate and showed MIC values of 0.5-1 µg/ml, 12 
(11%) were susceptible with MIC ≤0.05 µg/ml. Similarly, 
resistance rates to ciprofloxacin, levofloxacin, and ofloxacin 
were, 19% (n=21), 19% (n=21), and 22.6% (n=25) with MIC 
≥32 µg/ml, respectively (Figure1). Furthermore, 11% (n=12), 
9% (n=10), %4 (n=4), and 2.7% (n=3) of the isolates were, 
susceptible to nalidixic acid, ciprofloxacin, levofloxacin, and 
ofloxacin with MIC ≤0.5 µg/ml. 
ERIC-PCR Typing. Banding patterns of genomic DNA 
(range, 100 to 3500 bp) obtained by ERIC-PCR method are 
demonstrated in Figure 2a. The experiment was conducted 
twice, and reproducibility of the DNA patterns from the two 
gels was in the range of 98-100%. On the basis of the number 
and clarity of bands, their even distribution over the whole 
fingerprint, and discriminatory power, we identified 4 
clusters (fingerprint) and 6 individual clones (singleton) 
(Figure 2b). The largest one belonged to cluster-3 (Cl-3 
fingerprint) and consisted of 6 strains detected exclusively in 
UTI patients with length of hospital stay of 10-20 days. 
These strains showed high MIC (32 µg/ml) to all quinolones 
and had mutations in both gyrA and parC genes. Distinct 
ERIC-PCR banding patterns were obtained for cluster-1 (Cl-
1 fingerprint) consisting of 4 isolates recovered from 
bronchial aspirate and sputum of COPD and VAP patients 
with length of hospital stay of 15 to 25 days and exhibited 
high MIC (MIC 32 µg/ml) to all the quinolones tested. The 
remaining clusters were isolated either from patients’ blood 
or wound infections and abscesses with length of hospital 
stay of 15 to 25 days (Figure 2b). 
Alignment and phylogenetic tree analysis of gyrA gene. 
Evolutionary distance analysis and phylogenetic tree of gyrA 
gene extracted from highly quinolone resistant K. 
pneumoniae isolate 66, in comparison with similar 
sequences in NCBI/BLAST search database, showed a high 
degree of similarity with K. pneumoniae strain ha10 
(GenBank: JX123017.1) as illustrated in Figure 3. The 
alignment of the two sequences revealed 99.8% homology 
within 381 bp (Figure 3) 
 
Table 1.  Amino acid substitution mutations of gyrA and parC, clustral type, MIC, source of the samples, and length of hospitalization of 
6 quinolone resistant isolates of K. pneumoniae recovered from Kerman hospital, Iran  
Bacterial strain Amino acid 
gyrA 
Substitution 
parC 
Cluster type MIC 
(µg/ml) 
Isolated from Length of hospitalization 
(days) 
18 S83→I 
K154→R 
S171→A 
S129→A 
A141→V 
Cl-3 32 Urine 15 
20 S83→I 
K154→R 
S171→A 
S80→I  
S129→A  
 A141→V 
Cl-3 32 Urine 18 
27 K154→R 
S171→A 
S129→A 
A141→V 
Cl-3 32 Urine 17 
33 S83→I 
K154→R 
S171→A 
S80→I 
 S129→A 
A141→V 
Cl-1 32 Bronch 25 
65 K154→R 
S171→A 
ND Cl-6 32 Wound 21 
66 S83→F 
D87→A 
K154→R 
S171→A 
V190→G 
I191→F 
S129→A 
A141→V 
Cl-2 32 Sputum 20 
ND= not detected, A= Alanine, R= Arginine, I= Isoleucine, K= Lysine, S= Serine, V= Valine, F= Phenylalanine, G= Glycine, D= Aspartic acid. 
MIC was performed for nalidixic acid, ciprofloxacin, levofloxacin, and ofloxacin by E-test strip method. The inoculum concentration was CFU 1 × 108. 
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Fig. 1. Antibiotic susceptibility to four quinolones in K. pneumoniae strains isolated from a teaching hospital in Kerman, Iran. Nal, nalidixic 
acid; CIP, ciprofloxacin; LEV, levofloxacin; OF, ofloxacin. R= resistance, I= intermediate, S= sensitive. Breakpoint for each antibiotic was 
calculated according to the CLSI procedure 
 
 
 
 
Fig. 2a. Agarose gel electrophoresis of ERIC-PCR of K. pneumoniae stains isolated from clinical samples in a teaching hospital in Kerman, 
Iran. The banding pattern showed 4 distinct clusters and 6 singleton.  
 
Amino acid substitutions in gyrA and parC proteins. 
The PCR product of the gyrA and parC genes of the 6 K. 
pneumoniae isolates that showed high MIC to quinolones 
were sequenced, and amino acid sequences were evaluated 
for the presence of substitution mutation in certain positions. 
Six amino acid substitutions in gyrA and 3 amino acid 
substitutions in parC proteins were found in QR isolates 
(Figure 4a and 4b). In the case of gyrA protein, 3 point 
mutations and amino acid substitutions were detected at 
positions 83 (S → I), 154 (K → R), and 171 (S → A) in the 
strains 18, 20, and 33, respectively, while, double mutations 
were observed at positions 154 (K → R) and 171 (S → A) in 
the strains 27 and 65, respectively. Furthermore, strain 66 
carried up to 6 mutations at positions 83 (S → F), 87 (D → 
A), 154 (K → R), 171 (S → A), 190 (V → G), and 191 (I → 
F), in which 3 amino acid changes (Valine → Glycine, 
Aspartic → Alanine, and Serine → Phenylalanine) were 
unique to this strain and reported for the first time. This strain 
exhibited a high MIC (64 µg/ml) to all quinolones (p≤0.05).  
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Fig. 2b. Dendrogram showing genetic relatedness of 21 quinolone resistant strains of K. pneumoniae was determined by (ERIC)-PCR 
fingerprint patterns. 
 
 
Fig. 3. A) Evolutionary distance analysis and phylogenetic tree of gyrA gene extracted from highly quinolone resistant isolate 66 with 
references sequences of gyrA in GenBank. BLAST computes a pairwise alignment between a query and the database sequences searched 
in NCBI. B) A schematic illustration of the aligned sequence of gyrA from K. pneumoniae stain 66 with K. pneumoniae strain ha10 
(GenBank: JX123017.1).
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In the case of parC protein, 2 amino acid substitutions 
were located at codon positions 129 (S → A) and 141 (A → 
V) in the strains 18, 27, and 66. We also found 3 amino acid 
replacements at positions 80 (S → I), 129 (S → A), and 141 
(A → V) in the strains 20 and 33 (Figure 4b). The most 
common mutations were (S → I), (K → R), and (S → A) 
(p≤0.05). It is interesting to note that the rates of resistance 
to ciprofloxacin, levofloxacin, and ofloxacin were 
significantly higher for those isolates that carried 3 amino 
acid substitutions in gyrA and parC proteins. We found 
single isolate with an identical mutation in gyrA to that of 
reference K. pneumoniae strain WP_001281242.1. Table 1 
and Figure 5 shows amino acid substitution mutations in 
gyrA and parC, Cluster type, MIC, source of the samples, 
and length of hospitalization of the 6 strains of K. 
pneumoniae sequenced in this study. 
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Fig. 4. Amino acid sequence of a) gyrA and b) parC of 6 K. pneumoniae strains exhibiting high MIC to quinolones. The amino acid 
substitution mutations were marked with color and showed in boxes. Sequences of both gyrA and parC proteins were characterized using 
UniProt database and compared with reference sequences of Enterobacteriaceae gyrA subunit A with accession number WP_001281242.1 
and E. coli str. K-12 parC subunit A with accession number NC_000913.3. Dots indicate amino acids identical to the corresponding reference 
sequence. 
 
DISCUSSION 
Resistance to FQs in bacteria is mainly mediated by 
spontaneous mutations in the QRDR of gyrA and parC genes, 
either gyrA or parC, or both genes, especially at the highly 
conserved residues (Ser-83 and Asp-87) of gyrA [14]. In K. 
pneumonia, quinolone resistance is most commonly 
associated with specific mutations in gyrase and/or 
topoisomerase IV. Generally, mutation of type II enzyme 
confers ≤10-fold drug resistance. Selection for higher levels 
of resistance (∼10–100-fold) usually yields strains with 
mutations in both enzymes [15]. 
A little information is available on gyrA and parC 
mutations among drug-resistant nosocomial bacteria in Iran. 
In a study conducted on 50 A. baumannii isolates in Tehran 
hospitals, 44 isolates were resistant to quinolones, and 42 
isolates with double mutations in gyrA and parC genes 
showed a higher level of ciprofloxacin resistance compared 
to the 3 isolates with single mutations in gyrA or parC genes 
[16]. In another study, 23 out of 52 K. pneumoniae isolates 
were resistant to cephalosporins and/or quinolones; one 
isolate had the qnrS, and one harbored both aac (6’)-Ib-cr 
and qnrB genes [17]. 
In the present study, we investigated the antimicrobial 
susceptibility of 111 K. pneumoniae isolates collected from 
clinical specimens of patients in a teaching hospitals in 
Kerman, Iran. We found that the rate of full and moderate 
resistance to quinolones was unexpectedly high, which may 
be due to the extensive administration of these drugs in 
hospitalized patients. 
Analysis of the molecular nature of resistance suggests 
that MICs to quinolones in our isolates increased with the 
acquisition of additional mutations in gyrA and parC genes 
in the strains 18, 20, 27, 33, and 65. It seems that mutations 
in certain positions (83, 154, 171, and 191) of gyrA and parC 
genes resulted in high-level resistance to all quinolones. This 
was expected, as previous studies have shown that the 
progression from FQ susceptible towards resistant 
phenotype is a gradual process, starting from mutations in 
gyrA, the primary target of FQs, and followed by parC 
alterations that plays a complementary role in the 
development of higher levels of resistance [19]. This was 
confirmed by mutational analysis of strain 66, which had 6 
base substitution mutations in gyrA (3 amino acid changes, 
i.e., Valine → Glycine, Aspartic → Alanine, and Serine → 
Phenylalanine, were unique to this strain and reported for the 
first time) and 2 mutations in parC genes. The strain also 
showed the highest MIC (64 𝜇g/ml) to ciprofloxacin, 
levofloxacin, and ofloxacin. To our knowledge, there have 
been no reports of such mutations. Protein modelling 
analysis of gyrA protein from the strains 18, 33, and 66 
showed that its α/β structure is similar to those of other 
previously reported gyrA proteins, and the mutation may 
probably cause distortion of the helix. Dendrogram analysis 
by (ERIC)-PCR revealed 6 distinct fingerprints, the majority 
Aminoacid Mutation Substitution Quinolone Resistance 
J Med Microbiol Infec Dis                                                116                                                          2014 Vol. 2 No. 3 
of which belonged to clusters 3 and cluster 1. Isolates with 
similarity >80% were considered to be in one group. Cluster 
3 was more abundant among the isolates obtained from UTI 
patients. It is possible that this clone was spread among the 
UTI patients through contaminated catheters or 
contaminated urinary devices.      
Effect of mutations on increased quinolone resistance 
due to mutations in gyrA and parC was also reported 
worldwide [20]. It has been shown that in E. coli, 3 or 4 
mutations in both gyrA and parC genes are necessary to 
acquire high‐level resistance to ciprofloxacin, while double 
mutations at positions 83 (Ser83) of gyrA and 80 (Ser80) of 
parC cause only moderate‐level resistance [20]. Nakano et al. 
[21] reported that while a single amino acid change in gyrA, 
with or without a change in parC protein, was found in 14 
isolates of P. aeruginosa with decreased susceptibility to 
FQs, 3 higher-level FQ-resistant isolates had a double amino 
acid change in gyrA and a single amino acid change in parC. 
Similarly, a Thr-86 to Ile mutation in gyrA, at a position 
equivalent to the E. coli Ser-83 to Ala mutation, has been 
reported to be responsible for high-level resistance to FQs in 
Campylobacter jejuni in vivo [22].
 
 
Fig. 5. Amino acid substitution mutations of gyrA and parC, Clustral type, and number of mutations in gyrA and parC amplicons. 
 
In a study conducted on 61 ciprofloxacin-resistant 
isolates selected from 102 K. pneumoniae isolates, 4 major 
sequence types (STs) or clonal complexes (CCs), ST37, 
CC17 (consisting of ST17 and ST20), ST11, and CC528 
(consisting of ST528 and ST1130), were found, and they 
accounted for 48.2% of the isolates tested. Amino acid 
substitutions in the QRDR and the presence of plasmid-
mediated quinolone resistance (PMQR) genes, were detected 
in 20 (68.9%) and 18 (62.0%) isolates, respectively [23]. 
Another report revealed that 2 codons of Serine-83 and 
Aspartic acid-87 have the most frequent mutations, including 
Ser-83 → Phe (33%), Ser-83 → Tyr (20%), and Asp-87 → 
Asn (25%), Asp-87 → Ala (8%) that have high 
hydrophobicity compared to normal amino acids [24]. 
Weigel et al. [25] reported that low-level FQ resistance 
in E. coli was associated with single mutations in the gyrA 
protein, while high-level resistance required double 
mutations. They suggested with the exception of Seratia 
marcescens, that high-level resistance was associated 
primarily with alterations of the Serine or Threonine at 
position 83. 
Overall, the results of our study suggest that acquisition 
of mutations in gyrA and parC genes plays a significant role 
in the development of high-level resistance to quinolones in 
certain clustral lineages of K. pneumoniae. To control the 
dissemination of clusters with certain mutations and high-
level resistance in our hospital, excessive administration of 
quinolones must be discontinued. 
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